PAR Share Price Performance
AU$0.15
-0.13 (-46.55%)
84.5% undervalued intrinsic discount
AU$1.00
Fair Value
Price AU$0.15
kapirey AU$1.00
AmirV AU$5.50
Esdub
Fair ValueAU$1.00
Share Pricen/a
Narrative Update • May 17
Paradigm Biopharmaceuticals Limited Stock Price
- 3 Narratives written by author
- 3 Comments on narratives written by author
- 106 Fair Values set on narratives written by author
PAR Community Narratives
KA
Fair Value
·Fair Value AU$1 84.5% undervalued intrinsic discount
I am a shareholder and my investment thesis is maintained
3users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AM
Fair Value
·Fair Value AU$5.5 97.2% undervalued intrinsic discount
Paradigm Biopharmaceuticals Will Lead Osteoarthritis Treatment with Zilosul's FDA Success
19users have liked this narrative
3users have commented on this narrative
76users have followed this narrative
ES
Fair Value
·Fair Value AU$0 n/aintrinsic discount
Undervalued Potential Blockbuster
1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Undervalued Potential Blockbuster
Paradigm Biopharmaceuticals is developing an osteoarthritis treatment that looks simpler to make, easier to deliver, and less likely to run into surprise safety and regulator issues than a more complex rival approach. With key trial updates ahead, the company could narrow what the author sees as a big gap between its current market value and what similar programs are being priced at.Read more
Paradigm Biopharmaceuticals Will Lead Osteoarthritis Treatment with Zilosul's FDA Success
Paradigm Biopharmaceuticals is riding on a make‑or‑break moment as its osteoarthritis injection Zilosul moves through late-stage testing and awaits a key US regulator decision. If it works and gets cleared, it could offer a new option beyond today’s pain-focused treatments—but any trial or approval setback could quickly change the outlook.Read more
I am a shareholder and my investment thesis is maintained
Paradigm Biopharmaceuticals is riding on one big bet: a late-stage trial of an injectable treatment that aims to do more than just mask knee arthritis pain. The upside could be large if the trial works and a bigger partner gets involved, but there’s a real chance the study fails or regulators demand tougher proof before it can be sold.Read more
Trending Discussion
Recently Updated Narratives
KA
Phase III research update, interview with Dr. Rennie
Fair Value: AU$1 84.5% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
ES
Undervalued Potential Blockbuster
Fair Value: AU$0 0% overvalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AM
Paradigm Biopharmaceuticals Will Lead Osteoarthritis Treatment with Zilosul's FDA Success
Fair Value: AU$5.5 97.2% undervalued intrinsic discount
76 fair values setusers have set this as their fair value
3 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Paradigm Biopharmaceuticals Limited Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.069
- 24.53%
- -427,113.40%
- 146.8%
About PAR
- Founded
- 2014
- Employees
- n/a
- CEO
- WebsiteView website
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Recent PAR News & Updates
New Narrative • May 15
